|Articles|August 21, 2007

Silence Therapeutics Appoints New CEO

Author(s)BioPharm International Editors

Silence Therapeutics (London, England, www.silence-therapeutics.com) has appointed Jeffrey Scott Vick as Group CEO.

Silence Therapeutics (London, England, www.silence-therapeutics.com) has appointed Jeffrey Scott Vick as Group CEO. With this appointment, the company hopes to strengthen its core management team and expand its business partnerships. Vick has held senior positions in the healthcare industry in both Europe and the US, gaining experience as a business analyst and biotech venture capitalist. He has worked in the drug development sector for five years in senior management roles with DepoTech Corporation.

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

In 52-week phase 2 AMETHYST data, 27.2% of participants with cutaneous lupus reached clear or almost clear skin on litifilimab, up from 19.0% at week 24. (153 characters). Credit: Stock.Adobe.com/Love Employee

October 5th, 2026

Litifilimab Shows Sustained Skin Responses at 52 Weeks in Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus

Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.

FDA drug approval process, pharmaceutical regulatory compliance, food and drug administration certification, medical product approval concept, drug testing and approval | image credit: © Сергей Шиманович - © Сергей Шиманович - stock.adobe.com

October 5th, 2026

FDA Delays Novo Nordisk's Denecimig Over Facility Fixes

Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.

Group of Vaccine bottles. Medicine in ampoules. Glass vials for liquid samples in laboratory. | Image credit: © ronnarong - © ronnarong - stock.adobe.com

October 5th, 2026

Alvotech Wins FDA Nod for 2nd Simlandi Manufacturing Suite

Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.

Survodutide met co-primary weight loss endpoints in obesity and type 2 diabetes, but 18% of treated patients stopped due to gastrointestinal side effects. Credit: Stock.Adobe.com/Kateryna.

October 5th, 2026

Survodutide Meets Co-Primary Weight Loss Endpoints in Phase 3 SYNCHRONIZE-2 Trial in Obesity and Type 2 Diabetes

The glucagon/GLP-1 dual agonist hit both weight loss endpoints in phase 3, though gastrointestinal discontinuations and competitor data temper the readout.

October 2nd, 2026

The BioPharm Brief: Room Temperature, RNA, and ADCs

CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.

October 2nd, 2026

Amino Acid Count Determines Retatrutide's Biologic or Drug Classification

LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.

Close-up of an older person's hands, with the thumb of one hand pressing into the palm of the other, against a blurred teal background. | Image Credit: © eyepark - stock.adobe.com

October 2nd, 2026

Artiva to Present AlloNK Data Showing CAR T-Like B-Cell Depletion in Rheumatologic Diseases at ACR 2026

Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.

3D illustration of three golden spherical nanoparticles, one shown in cross-section to reveal a layered lipid shell, with a blue helical nucleic acid strand winding around them against a black background. | Image Credit: © Love Employee - stock.adobe.com

October 2nd, 2026

Novartis Licenses Abogen's mRNA-Encoded CD19xCD3 T-Cell Engager ABO2203 for Autoimmune Diseases

Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.